Stockscreener 앱 받기
21.65
4.20%
-0.95
시간 외 거래:
21.65
전일 마감가:
$22.60
열려 있는:
$22.59
하루 거래량:
137.93K
Relative Volume:
0.52
시가총액:
$381.37M
수익:
$116.88M
순이익/손실:
$-25.09M
주가수익비율:
-154.64
EPS:
-0.14
순현금흐름:
$-20.74M
1주 성능:
-2.35%
1개월 성능:
+28.72%
6개월 성능:
+104.63%
1년 성능:
+85.04%
1일 변동 폭
$21.27
$23.01
1주일 범위
$20.98
$23.20
52주 변동 폭
$7.4843
$29.82
Rigel Pharmaceuticals Stock (RIGL) Company Profile
명칭
Rigel Pharmaceuticals
전화
650-624-1100
주소
611 GATEWAY BOULEVARD, SUITE 900, SOUTH SAN FRANCISCO, CA
RIGL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RIGL
Rigel Pharmaceuticals
|
21.65 | 381.37M | 116.88M | -25.09M | -20.74M | -0.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.68 | 118.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.98 | 73.95B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
655.13 | 39.81B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.31 | 34.99B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
123.77 | 29.67B | 3.30B | -501.07M | 1.03B | -2.1146 |
Rigel Pharmaceuticals Stock (RIGL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-04-03 | 재개 | Piper Sandler | Neutral |
| 2022-06-09 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-06-08 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2022-06-08 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-03-23 | 개시 | B. Riley Securities | Neutral |
| 2020-11-09 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2019-11-15 | 재개 | Cantor Fitzgerald | Overweight |
| 2019-09-26 | 재개 | JP Morgan | Overweight |
| 2019-03-01 | 재확인 | Cantor Fitzgerald | Overweight |
| 2018-08-27 | 개시 | Citigroup | Buy |
| 2018-05-02 | 재확인 | Cantor Fitzgerald | Overweight |
| 2017-12-21 | 재개 | Piper Jaffray | Overweight |
| 2017-12-15 | 개시 | Cantor Fitzgerald | Overweight |
| 2017-11-06 | 재개 | H.C. Wainwright | Buy |
| 2017-03-09 | 재확인 | H.C. Wainwright | Buy |
| 2016-08-31 | 재확인 | H.C. Wainwright | Buy |
| 2016-08-30 | 재확인 | Piper Jaffray | Overweight |
| 2016-07-13 | 개시 | H.C. Wainwright | Buy |
| 2016-06-13 | 개시 | Piper Jaffray | Overweight |
| 2016-04-22 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2013-04-08 | 재확인 | Stifel | Buy |
| 2012-11-29 | 개시 | UBS | Neutral |
| 2012-11-06 | 재확인 | Oppenheimer | Outperform |
| 2012-03-26 | 개시 | Canaccord Genuity | Hold |
| 2010-12-10 | 다운그레이드 | MP Advisors | Outperform → Market Perform |
모두보기
Rigel Pharmaceuticals 주식(RIGL)의 최신 뉴스
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Receives $36.20 Average Target Price from Analysts - MarketBeat
When (RIGL) Moves Investors should Listen - Stock Traders Daily
Rigel Pharmaceuticals, Inc. Reports Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2017 - Marketscreener.com
Rigel Pharmaceuticals (RIGL) Stock Price, News & Analysis - MarketBeat
Rigel Pharmaceuticals' SWOT analysis: diverse portfolio fuels growth, stock faces headwinds - Investing.com Australia
Rigel's fostamatinib enters Phase 1 trial for sickle cell treatment - MSN
Rigel enrols first subject in Phase I sickle cell disease therapy trial - Clinical Trials Arena
Cantor Fitzgerald Estimates RIGL FY2025 Earnings - Defense World
Rigel Pharmaceuticals' (RIGL) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Rigel's Fostamatinib Being Studied by National Institute of Health in Patients with Sickle Cell Disease - Marketscreener.com
Rigel's fostamatinib enters Phase 1 trial for sickle cell treatment By Investing.com - Investing.com Australia
Rigel Pharmaceuticals enrolls first patient in Phase 1 study of fostamatinib - TipRanks
Equities Analysts Offer Predictions for RIGL FY2025 Earnings - MarketBeat
JW Pharmaceutical gains approval for immune thrombocytopenia treatment TavalisseCHOSUNBIZ - 조선비즈
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Shares Sold by Assenagon Asset Management S.A. - MarketBeat
Long Term Trading Analysis for (RIGL) - Stock Traders Daily
KFDA approves immune thrombocytopenia treatment Tavalisse from Rigel PharmaceuticalsCHOSUNBIZ - 조선비즈
Assenagon Asset Management S.A. Sells 30,987 Shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - Defense World
Rigel Pharmaceuticals Shares Preliminary Financial Results in Recent 8-K Filing - Defense World
Barclays PLC Has $442,000 Stock Holdings in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - Defense World
Barclays PLC Grows Position in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - MarketBeat
Short Interest in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Rises By 27.1% - MarketBeat
Wall Street Analysts Predict a 75.79% Upside in Rigel (RIGL): Here's What You Should Know - MSN
Retail Investors Bet On Anavex Lifesciences Stock To Outperform Novavax, Rigel Pharma In Q1 On Alzheimer’s Drug Buzz - MSN
HC Wainwright Brokers Raise Earnings Estimates for RIGL - Defense World
Rigel (RIGL) Upgraded to Buy: Here's Why - MSN
Equities Analysts Set Expectations for RIGL Q4 Earnings - MarketBeat
Research Analysts Issue Forecasts for RIGL FY2024 Earnings - Defense World
Rigel Pharmaceuticals Seeks for Acquisitions -January 16, 2025 at 11:15 am EST - Marketscreener.com
Cantor Fitzgerald Has Positive View of RIGL FY2024 Earnings - MarketBeat
Rigel Pharmaceuticals' (RIGL) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Rigel forecasts revenue growth in 2025, reports Q4 sales - Investing.com India
RIGLRigel Pharmaceuticals Inc. (New) Latest Stock News & Market Updates - StockTitan
Rigel Pharmaceuticals sets 2025 sales outlook above estimates - MSN
Rigel forecasts revenue growth in 2025, reports Q4 sales By Investing.com - Investing.com South Africa
Rigel Provides Business Update and 2025 Outlook - PR Newswire
(RIGL) Technical Data - Stock Traders Daily
Rigel announces R289 granted Orphan Drug designation by FDA for MDS - TipRanks
Rigel Pharmaceuticals Gets FDA Orphan-Drug Designation for R289 - MarketWatch
Rigel Announces R289 Granted Orphan Drug Designation by the FDA for MDS - Quantisnow
Rigel's MDS Drug R289 Receives FDA Orphan Drug Status, Boosting Market Exclusivity Potential - StockTitan
Rigel to Present at the 43rd Annual J.P. Morgan Healthcare Confe - GuruFocus.com
Rigel to Present at the 43rd Annual J.P. Morgan Healthcare Conference - PR Newswire
Jane Street Group LLC Lowers Holdings in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - MarketBeat
Rigel Pharmaceuticals (RIGL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.95%
2.39%
자본화:
|
볼륨(24시간):